Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal cell carcinoma

G D Long1

  • 1Section on Hematology/Oncology, Comprehensive Cancer Center of Wake Forest University, Bowman Gray School of Medicine, Winston-Salem, NC 27157, USA.

Current Opinion in Oncology
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated sensing layer of bacterial cellulose and polyethyleneimine to achieve high sensitivity of ST-cut quartz surface acoustic wave formaldehyde gas sensor.

Journal of hazardous materials·2019
Same author

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Bone marrow transplantation·2017
Same author

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.

Bone marrow transplantation·2013
Same author

Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.

Bone marrow transplantation·2012
Same author

Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Bone marrow transplantation·2011
Same author

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Bone marrow transplantation·2011
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Recent advances in renal cell carcinoma research include understanding its molecular biology and identifying new prognostic factors. Combination immunotherapy shows promise, but current tumor cell vaccines offer limited benefit.

Area of Science:

  • Urologic oncology
  • Cancer molecular biology
  • Immunotherapy

Background:

  • Renal cell carcinoma (RCC) presents significant challenges in urologic oncology.
  • Understanding RCC molecular biology and prognostic factors is crucial for treatment.
  • Nephron-sparing procedures are being refined for select patient groups.

Purpose of the Study:

  • To summarize recent advancements in understanding renal cell carcinoma.
  • To review new prognostic factors impacting patient outcomes after nephrectomy.
  • To evaluate the efficacy of current therapeutic strategies for RCC.

Main Methods:

  • Review of recent studies on RCC molecular biology.
  • Analysis of prognostic factors for patients undergoing nephrectomy.

Related Experiment Videos

  • Evaluation of immunotherapy combinations (interleukin-2 and interferon-alpha) with chemotherapy.
  • Assessment of autologous tumor cell vaccine efficacy through prospective trials.

    • Main Results:

    • Progress in understanding RCC molecular mechanisms and identifying prognostic indicators.
    • Elective nephron-sparing surgery is better defined for specific patient populations.
    • Combination immunotherapy (IL-2 and interferon-alpha) shows greater activity than monotherapy, potentially enhanced by chemotherapy.
    • No novel chemotherapeutic agents have emerged as active.
    • Current autologous tumor cell vaccines demonstrate minimal therapeutic advantage.

    Conclusions:

    • Combination immunotherapy, particularly with chemotherapy, warrants further investigation for RCC.
    • Nephron-sparing approaches can be safely applied to carefully selected RCC patients.
    • Further research is needed to identify effective chemotherapeutic agents and improve vaccine strategies for renal cell carcinoma.